247 related articles for article (PubMed ID: 36105233)
21. Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies.
Talaei F; Atyabi F; Azhdarzadeh M; Dinarvand R; Saadatzadeh A
Eur J Pharm Sci; 2013 Jul; 49(4):712-22. PubMed ID: 23665411
[TBL] [Abstract][Full Text] [Related]
22. Non-viral Delivery of Nucleic Acids: Insight Into Mechanisms of Overcoming Intracellular Barriers.
Durymanov M; Reineke J
Front Pharmacol; 2018; 9():971. PubMed ID: 30186185
[TBL] [Abstract][Full Text] [Related]
23. Arginine-based poly(ester amide) nanoparticle platform: From structure-property relationship to nucleic acid delivery.
You X; Gu Z; Huang J; Kang Y; Chu CC; Wu J
Acta Biomater; 2018 Jul; 74():180-191. PubMed ID: 29803783
[TBL] [Abstract][Full Text] [Related]
24. Plant-Derived Exosomes as a Drug-Delivery Approach for the Treatment of Inflammatory Bowel Disease and Colitis-Associated Cancer.
Cai Y; Zhang L; Zhang Y; Lu R
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456656
[TBL] [Abstract][Full Text] [Related]
25. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
26. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse.
Maisel K; Ensign L; Reddy M; Cone R; Hanes J
J Control Release; 2015 Jan; 197():48-57. PubMed ID: 25449804
[TBL] [Abstract][Full Text] [Related]
27. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.
Date AA; Hanes J; Ensign LM
J Control Release; 2016 Oct; 240():504-526. PubMed ID: 27292178
[TBL] [Abstract][Full Text] [Related]
28. Nanocomposite systems for precise oral delivery of drugs and biologics.
Andretto V; Rosso A; Briançon S; Lollo G
Drug Deliv Transl Res; 2021 Apr; 11(2):445-470. PubMed ID: 33534107
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease.
Si XY; Merlin D; Xiao B
World J Gastroenterol; 2016 Sep; 22(34):7718-26. PubMed ID: 27678353
[TBL] [Abstract][Full Text] [Related]
30. Non-viral nucleic acid containing nanoparticles as cancer therapeutics.
Kozielski KL; Rui Y; Green JJ
Expert Opin Drug Deliv; 2016 Oct; 13(10):1475-87. PubMed ID: 27248202
[TBL] [Abstract][Full Text] [Related]
31. Corona Virus Disease-19 pandemic: The gastroenterologists' perspective.
Dhar J; Samanta J; Kochhar R
Indian J Gastroenterol; 2020 Jun; 39(3):220-231. PubMed ID: 32783168
[TBL] [Abstract][Full Text] [Related]
32. Improving silymarin oral bioavailability using silica-installed redox nanoparticle to suppress inflammatory bowel disease.
Nguyen TT; Trinh NT; Tran HN; Tran HT; Le PQ; Ngo DN; Tran-Van H; Van Vo T; Vong LB; Nagasaki Y
J Control Release; 2021 Mar; 331():515-524. PubMed ID: 33616078
[TBL] [Abstract][Full Text] [Related]
33. Yeast Microcapsule-Mediated Targeted Delivery of Diverse Nanoparticles for Imaging and Therapy via the Oral Route.
Zhou X; Zhang X; Han S; Dou Y; Liu M; Zhang L; Guo J; Shi Q; Gong G; Wang R; Hu J; Li X; Zhang J
Nano Lett; 2017 Feb; 17(2):1056-1064. PubMed ID: 28075596
[TBL] [Abstract][Full Text] [Related]
34. Biological properties and therapeutic effects of plant-derived nanovesicles.
Di Gioia S; Hossain MN; Conese M
Open Med (Wars); 2020; 15(1):1096-1122. PubMed ID: 33336066
[TBL] [Abstract][Full Text] [Related]
35. Novel drug delivery strategies for the treatment of inflammatory bowel disease.
Kesisoglou F; Zimmermann EM
Expert Opin Drug Deliv; 2005 May; 2(3):451-63. PubMed ID: 16296767
[TBL] [Abstract][Full Text] [Related]
36. Stimuli-responsive liposomes for the delivery of nucleic acid therapeutics.
Movahedi F; Hu RG; Becker DL; Xu C
Nanomedicine; 2015 Aug; 11(6):1575-84. PubMed ID: 25819885
[TBL] [Abstract][Full Text] [Related]
37. Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease.
Liu W; Dong Z; Liu K; Lu Y; Wu W; Qi J; Chen Z
Int J Pharm; 2021 May; 600():120461. PubMed ID: 33711470
[TBL] [Abstract][Full Text] [Related]
38. Advances in Nanoparticle-based Delivery of Next Generation Peptide Nucleic Acids.
Malik S; Asmara B; Moscato Z; Mukker JK; Bahal R
Curr Pharm Des; 2018; 24(43):5164-5174. PubMed ID: 30657037
[TBL] [Abstract][Full Text] [Related]
39. Nanotechnology for delivery of peptide nucleic acids (PNAs).
Gupta A; Bahal R; Gupta M; Glazer PM; Saltzman WM
J Control Release; 2016 Oct; 240():302-311. PubMed ID: 26776051
[TBL] [Abstract][Full Text] [Related]
40. Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives.
Dos Santos AM; Carvalho SG; Meneguin AB; Sábio RM; Gremião MPD; Chorilli M
J Control Release; 2021 Jun; 334():353-366. PubMed ID: 33901582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
